Previous 10 | Next 10 |
2023-09-27 09:22:17 ET More on Ocuphire Pharma, Viatris, etc. Why 5%-Yielding Viatris Hasn't Doubled Yet Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs Market Viatris: Turning Point For Cheap Pharma Stock Viatris in talks to sell European OTC a...
Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents PR Newsw...
2023-09-22 05:00:26 ET Worried that the Federal Reserve is driving our economy off a cliff? I’ve got two words for you: Drugs ‘n diapers . Actually, I forgot one. Dividends . These companies are about as recession-resistant as they come. Let’...
2023-09-14 09:18:00 ET Inflation is giving investors more of an incentive to find ways to increase their income. If you have a decent nest egg saved up, you can use it to invest in dividend stocks to improve your financial position. It could be a better alternative than dipping into your sa...
2023-09-14 06:07:30 ET Summary Viatris is a healthcare corporation formed through a merger, with a diversified global portfolio and a focus on ophthalmology, gastrointestinal, and dermatology therapeutic areas. Despite its elevated debt load, Viatris has demonstrated strong financ...
Viatris Named to TIME's World's Best Companies 2023 List PR Newswire PITTSBURGH , Sept. 12, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to TIME's World's Best Companies 2023 list ...
2023-09-09 07:20:00 ET On average, healthcare stocks haven't kept up with the gains made by the rest of the market this year. While the S&P 500 index is up by more than 17% year to date, that sector's stocks are down by nearly 3%. That trend, though, created some great opportunities...
2023-09-06 13:16:14 ET More on Viatris Seeking Alpha’s Quant Rating on Viatris Historical earnings data for Viatris Dividend scorecard for Viatris Financial information for Viatris Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs M...
2023-09-05 06:42:18 ET More on Viatris Seeking Alpha’s Quant Rating on Viatris Historical earnings data for Viatris Dividend scorecard for Viatris Financial information for Viatris Viatris Emerges As Challenger In Lucrative Anti-Obesity Drugs M...
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV PR Newswire Tentative approval will help enhance access to WHO-recommended paediatric regimen wi...
News, Short Squeeze, Breakout and More Instantly...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...
2024-07-15 10:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...